News

Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...
Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...
Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to read an analysis of REGN stock now.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Regeneron has not disclosed any specific information regarding its anticipated financial performance for the second quarter 2025, which could lead to investor uncertainty and speculation.
Moderna has a deep pipeline of promising mRNA candidates that stand to boost business. Regeneron is looking at label ...
Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.
Regeneron Pharmaceuticals has recently launched a Phase 2 trial, testing the waters with a potential breakthrough in melanoma ...
Regeneron announced FDA accelerated approval for Lynozyfic™ to treat advanced multiple myeloma in heavily pre-treated patients.
With the Trump administration poised to hike tariffs on Canadian goods to 35%, the equities market ended on a down note ...